Related Experiment Video
Updated: Jul 30, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Tumor necrosis factor blocking agents: a review. Part II: safety and recommendations]
C Rodríguez Moreno1, P López Vázquez, C Durán Parrondo
1Servicio de Farmacología Clínica, Complexo Hospitalario Universitario, Santiago de Compostela, A Coruña. carlos.rodriguez.moreno@sergas.es
Anales De Medicina Interna (Madrid, Spain : 1984)
|March 29, 2006
Summary
Monoclonal antibodies targeting tumor necrosis factor (TNF) are effective for autoimmune diseases like rheumatoid arthritis. However, these TNF-blockers carry risks that necessitate careful management and recommendations for use.
Area of Science:
- Immunology
- Pharmacology
Context:
- Autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease involve chronic inflammation.
- Tumor necrosis factor (TNF) plays a key role in the inflammatory processes of these conditions.
Purpose:
- To review the clinical evidence on the benefits and risks of using TNF-blockers in their approved indications.
- To offer practical recommendations for managing autoimmune conditions with TNF-blockers.
Summary:
- Monoclonal antibodies targeting TNF are effective in reducing symptoms and disease progression in several autoimmune conditions.
- The use of TNF-blockers can disrupt immune balance, leading to potential risks that require careful consideration.
- This review synthesizes current evidence to guide the safe and effective application of TNF-blockers.
Impact:
- Provides clinicians with evidence-based guidance for optimizing TNF-blocker therapy in autoimmune diseases.
- Highlights the importance of balancing therapeutic benefits against potential adverse effects associated with TNF inhibition.
- Contributes to improved patient outcomes through informed decision-making in the management of chronic inflammatory conditions.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...